An updated suite of viral vectors for *in vivo* calcium imaging using local and retro-orbital injections.

Sverre Grødem*, Ingeborg Nymoen*, Guro Helén Vatne, Valgerdur Björnsdottir, Kristian Kinden Lensjø^{#,+}, Marianne Fyhn[#]

Center for Integrative Neuroplasticity, Department of Bioscience, University of Oslo, Norway

*these authors contributed equally

[#]shared senior authors

⁺Correspondence may be addressed to: kristian.lensjo@ibv.uio.no

ABSTRACT Calcium imaging using genetically encoded indicators (GECIs) is a widely adopted method to measure neural activity in modern neuroscience. Here, we explore the use of systemically administered viral vectors for brain-wide expression of GECIs, and adapt novel GECIs to optimize signal-to-noise. We show that systemic injections of PHP.eB AAVs to express GECIs is a highly promising technique for imaging neural activity and circumvent the need for transgenic GECI expressing mouse lines. We also establish the use of novel soma-targeted GECIs that outperform current Ca²⁺ indicators using both systemic and local virus injections.

INTRODUCTION

The use of microscopy to measure the activity of neurons is widely applied in modern neuroscience. With the development of genetically encoded Ca²⁺ indicators (GECIs) there has been rapid advances in response kinetics, sensitivity and brightness of Ca²⁺ sensors (e.g. ^{1,2}), of which the GCaMP sensors are the most prominent. These engineered proteins contain a Ca²⁺ binding motif and a circularly permuted green fluorescent protein that brightens when Ca²⁺ is present. Using GECIs for activity measurements allows for cell-type targeted recordings, repeated measurements of the same cells for up to several months and recordings from large populations of neurons. Ideally, GECIs should be uniformly expressed across the neuronal population. Overexpression in a subset of cells can lead to intracellular aggregation and eventually cell death.

To achieve this, various methods to introduce the genetic constructs into cells have been explored. An often preferred method for introducing GCaMP into neurons is by way of transgenic animal models(e.g.^{3,4,5}). These models allow for strong, even and sustained expression throughout life that can be targeted to specific cell types. However, transgenic GCaMP mice require intricate breeding schemes that come with high costs, both financial and

for animal welfare. They also depend on driver lines that prevent the use of other transgenics³. Moreover, because the GECIs are expressed throughout development, frequent ictal activity has been reported for several such mouse strains⁶, questioning their reliability.

GCaMP can also be delivered to cells by a viral vector, either through a local injection directly into the tissue of interest (e.g.⁷) or by intracerebroventricular injections⁸. Furthermore, using adeno-associated virus (AAV) serotype 9 which crosses the blood-brain-barrier⁹ in neonatal mice, GCaMP may be introduced through an intravenous injection into the tail vein, temporal vein¹⁰ or transverse sinus¹¹. However, these administration techniques are technically challenging. They also come with the risk of overexpression of the GECI because of the young age at the time of injection, and extended period from injections to experiments which may lead to cell damage or ictal events. Local injections of viral vectors tend to lead to highly variable expression depending on the concentration of virus particles and is often associated with cell damage or death¹².

In contrast to AAV9, the recently developed AAV serotype PHP.eB has been shown to cross the blood-brain barrier in adult animals and efficiently transduce neurons across the brain¹³, suggesting that genes could be delivered via intravenous injections¹⁴. Importantly, such injections can be performed at any stage in development and thus prevent accumulation of GCaMP and disturbing Ca²⁺ homeostasis during sensitive parts of development. Moreover, this would enable brain-wide expression of the GECI in combination with other transgenic models for e.g. cell-type specific activity perturbations. In contrast to tail vein and other intravenous injection procedures, injections into the retro orbital (RO) sinus can be performed with minimal training. RO injections are quick, non-invasive, and impose little stress to the animals compared to other methods¹⁵.

Here we present a GECI screening in mice applying the RO injection method for systemic viral delivery and assess functionality using widefield and two-photon laser-scanning microscopy. All viral vectors were tested by both RO and local injections to verify the efficiency of the construct. We show that several recently developed GECIs are highly suitable for this application and give rise to uniform and stable expression for many weeks and can be combined with other transgenic models for e.g. cell-specific expression of optogenetic or chemogenetic receptors. Finally, we combine modern constructs for restricting GCaMP localization to the cell soma^{16, 17} with the most recent iterations of jGCaMP, the jGCaMP8¹⁸ sensors. With these novel soma-targeted GECIs we observe remarkable signal-to-noise ratio, using both systemic or local virus administration.

RESULTS

Performance screening of existing GECIs using RO injections

We initially screened the performance of 10 existing GECI variants administered by RO or local injections in high titre PHP.eB serotype AAVs. In addition, two fluorescent proteins were expressed by RO and local PHP.eB injections (mNeonGreen expressed under a CAG promoter, and floxed tdTomato was injected in PV-Cre mice). Briefly, pairs of mice were randomly assigned a GECI-expressing AAV and evaluated at 2, 4 and 6 weeks using widefield and two-photon imaging through a cranial window, followed by histological analysis (**Fig. 1a**). The majority of screened GECIs, which are variations of GCaMP, were not sufficiently bright for in-vivo calcium imaging following systemic virus administration (**Fig. 1, Table 1**). The most widely used GECI, GCaMP6f was undetectable at reasonable laser power when expressed from an intravenously injected AAV, likely due to reduced multiplicity of infection (MOI) associated with intravenously administered viruses. Notably, GCaMP6f was present and visible in the tissue after 6 weeks, but only when using very high laser power (>140 mW output at the objective) which would not be sustainable for functional experiments (**Fig. 2a**). In an attempt to improve the brightness, we tested both double and triple injection volumes of RO administered GCaMP6f, but the resulting expression was still too dim to image at reasonable laser power (data not shown).

Figure 1: GECI screening after local or retro-orbital (RO) virus injections. **A:** Experimental overview indicating the two injection approaches, and the methods used to monitor the expression. **B:** Example images from widefield fluorescence microscopy of two GECIs expressed by RO (two upper panels) or local (lower panel) virus injections 2, 4 and 6 weeks after injection. Scale bar indicates 1 mm. **C:** Example images from *in vivo* two-photon microscopy of a GECI expressed by RO or local virus injection. Scale bar indicates 250 μm. **D:** GECI expression at different depths in cortex after RO injection. Scale bar indicates 150 μm.

Of the more recently developed GECIs; jGCaMP7s, jGCaMP8s and jGCaMP8m were all sufficiently bright for use with systemic viruses (**Fig. 2a**). The expression of these indicators was visible two weeks after injection, and the expression remained stable across weeks (**Fig. 1C**), with no indication of intracellular aggregation. Of these, jGCaMP7s displayed the lowest neuropil signal but also the slowest response kinetics, as reported earlier². While jGCaMP8f is reported to be brighter than previous “fast” iterations, it was not sufficiently bright for imaging. Similarly to GCaMP6f, we attempted to inject a higher volume spread out over several days, but this did not improve the brightness sufficiently. Importantly, post-mortem histological analysis indicated that brightness of the GECI was the determining factor, as the expression of GCaMP when labeled with a GFP antibody was comparable between GECIs with very different *in vivo* performance (**Fig. 2b**). Overall, the histology and *in vivo* imaging matched previous reports on PHP.eB infection¹⁹, with fairly even expression across the cortex and the

highest density in cortical layer 5 (**Fig. 1d, 2b**). This was true for the visual cortex, somatosensory, retrosplenial and motor cortex. (**Fig. S2**). In the hippocampus, we observed almost no labeling, apart from very dense labeling in area CA2 (**Fig. S2**).

Previous reports on transgenic GECI expressing mouse lines have shown that ictal events can occur frequently in such models. In contrast to these models, none of the GECIs we tested by RO injection showed signs of ictal activity (measured by widefield fluorescence imaging) (example data shown in **Fig S1**).

Figure 2: *In vivo* GECI screening after retro-orbital virus injections. **A:** Example images from five different GECIs at different magnification. Note that GCaMP6f and jGCaMP7f were not detectable using at reasonable illumination intensity (40-50mW at 920 nm). These images were acquired using 150mW laser power for testing purposes only. The recently developed jGCaMP7s, 8s and 8m were sufficiently bright and were imaged using 50mW. Scale bar indicates 250 μm (upper panel) and 100μm (lower panel). All images shown are average intensity projections from 2000 frames with identical adjustments to brightness and contrast. **B:** Histology images from primary visual cortex six weeks after RO injection. The expression of GCaMP6f and jGCaMP8m were similar showing strong expression throughout cortex, in particular in layer 5 neurons.

Soma targeting of existing GECIs

While sufficient brightness for imaging is a requirement for any GECI to be viable, there are many factors to consider when selecting the optimal sensor for a given experiment. The newer iterations of jGCaMP feature improved kinetics and a much higher $\Delta F/F$ relative to past versions. Accordingly, provided that brightness is sufficient, the most recent jGCaMP iteration,

jGCaMP8, is preferred over past versions. However, we also observed a substantial amount of background signal, which is usually attributed to localization of the GECI to neuronal processes (neuropil). To combat this issue, we first tested three recently developed soma-targeted GCaMPs, Ribo-GCaMP6m¹⁷, Soma-GCaMP6f and Soma-GCaMP7f that confine GCaMP to the soma to effectively reduce background noise from neuropil¹⁶. We observed reduced neuropil signals in locally injected animals, but neither were sufficiently bright for in-vivo imaging following RO AAV injection (**Table 1**).

Table 1: Overview of initial GECI screening with virus titer and addgene reference indicated.

GECI	Titre (VG/ml)	Brightness at 50mW	Neuropil	Local injection brightness	Addgene plasmid #
GCaMP6f	2.44E+13	none	NA	medium	100837
Soma-GCaMP6f	2.04E+13	low	low	medium	158756
jGCaMP7f	2.04E+13	low	NA	medium	104488
Soma-GCaMP7f	1.53E+13	low	low	medium	158760
jGCaMP7s	1.11E+13	high	medium	high	104487
jGCaMP8f	1.04E+13	low	high	medium	162376
jGCaMP8m	9.43E+12	medium	high	high	162375
jGCaMP8s	1.29E+13	high	high	high	162374
jRexGECO	9.36E+12	high	low	high	169259*
Ribo-GCaMP6m	1.86E+13	low	low	low	158777
CAG-mNeonGreen	1.09E+13	high	NA	high	99134
TdTomato #	8.83E+12	high	NA	NA	28306

*Flex-TdTomato was tested in PV-Cre mice

*jRexGECO expressed from a hSyn promoter was made and used in this manuscript

Expression of novel soma-targeted GECIs

We hypothesized that the brightest GECIs, the new GCaMP8s, would also work in combination with the EE-RR Soma tag. We therefore constructed Soma (EE-RR) tagged versions of the most promising jGCaMP8 variants (jGCaMP8m and s). The EE-RR Soma-jGCaMP8, was

comparably bright to the unaltered jGCaMP8 at 2-4 weeks post injection, with an improved signal to noise ratio (**Fig. 3, left and middle panel**). In addition to improving the distinction between individual neurons, the reduced neuropil signal allowed us to image dense populations of neurons at greater depths without increasing laser power (**Fig 3, lower panel**). In comparison to EE-RR soma targeting and other non-soma targeted GECIs, ribosome-tethered GCaMP expression has been reported to show drastically reduced brightness of the attached GCaMP, demanding high laser intensity for *in vivo* imaging. However, the reported specificity of Ribo-GCaMP expression is more restricted to the soma, making it more favorable for population imaging. We therefore constructed Ribo-jGCaMP8m and s (RL10) and tested the suitability of the brightest sensor, Ribo-jGCaMP8s, for systemic injections. In line with the previously observed reduction of brightness of GCaMP6m by the Ribo tag, ribo-tagged GCaMPs only displayed dim signal confined to a small space in the soma 2 weeks after injection. However, after 4-6 weeks the signal had improved, and was sufficiently bright at reasonable laser power. As previously reported for local injections of Ribo-GCaMP6m, the expression was strictly confined to the soma, with little to no visible neuropil signal (**Fig. 3, right panel**). Ribo-jGCaMP8f and Soma-jGCaMP8f were also created, but were not tested in this paper due to the low brightness of jGCaMP8f when tested with RO injections.

Figure 3: Soma-targeted GECIs expressed by retro orbital injections. Left and middle panels show EE-RR soma targeting at two imaging depths and magnifications, while the right panel shows ribosome-tethered expression. For both methods we observed high signal-to-noise and strong expression after six weeks. At 350μm below the surface the density of labeled cells was very high. In contrast to the EE-

RR soma-targeted approach, ribosome-tethered GCaMP was not detectable until 4-6 weeks after injection. All images shown are average intensity projections from 2000 frames with identical adjustments to brightness and contrast. Scale bars indicate 150 and 50 μm , respectively.

Local injections of novel soma-targeted GECIs

Despite the promising nature of RO injected GECIs for population imaging, some experiments still require local expression for Ca^{2+} imaging. We therefore tested our adapted constructs for EE-RR and ribosome-tethered jGCaMP8 and compared their performance with regular jGCaMP8 after local virus injections. Similar to the RO injected animals, we observed strong signals from both EE-RR and regular jGCaMP8 (**Fig. 4**), with reduced neuropil in the EE-RR version. Ribo-jGCaMP8 was relatively dim 2 weeks after injection, but after 6 weeks showed high brightness. Moreover, both Ribo-jGCaMP8 versions were highly selective for expression limited to the soma, with no visible neuropil signal.

Figure 4: GECIs expressed by local injection of PHP.eb virus. **A:** Example images from upper layers of primary visual cortex acquired six weeks after virus injection. jGCaMP7s and 8s (left panels) were very bright but show strong neuropil contamination of the signal. EE-RR soma targeting (middle panels) improved this somewhat, while ribosome-tethering lead to a dramatic improvement. All images shown are average intensity projections from 2000 frames with identical adjustments to brightness and contrast. Scale bar indicates 100 μm . **B and C:** Examples of automatic cell detection from Suite2p and example traces of Ca^{2+} activity.

High signal-to-noise using novel soma-targeted GECIs

We next quantified $\Delta f/f_0$ from the neuropil surrounding each neuron and compared it to the somatic signal for a selection of the GECIs tested, based on the methods from Shemesh et al., 2020¹⁶. The boundaries used were defined by Suite2p. In line with our early observations, we found that both Ribo- and soma-targeted GECIs had higher signal-to-noise compared to jGCaMP8s (**Figure 5**).

Figure 5: Quantification of signal-to-noise in GECIs. $\Delta f/f_0$ in soma over $\Delta f/f_0$ in neuropil, where f_0 is defined as the lower tenth percentile of F_{soma} or F_{neuropil} respectively.

Table 2: Soma-targeted GECI constructs made in this work.

GECI	Titre (VG/ml)	Brightness at 50mW	Neuropil	Local injection brightness	Addgene plasmid #
Soma-jGCaMP8m	1.93E+13	high	low	high	169257
Soma-jGCaMP8s	1.73E+13	high	low	high	169256
Soma-jGCaMP8f*	NA	NA	NA	NA	169258
Ribo-GCaMP8m	3.27E+13	NA	none	high	167574
Ribo-GCaMP8s	2.80E+13	medium	none	high	167572
Ribo-GCaMP8f*	NA	NA	NA	NA	167573

*not tested.

Applications of systemic GECI injections

One of the challenges with using traditional approaches to express GECIs is combining several transgenic constructs; local injections of two or more viruses often leads to competition and low co-expression, while transgenic GECI animals prevent the use of other transgenic lines due to the driver lines required for uniform GECI expression. To test the suitability of RO injections for this purpose, we used PV-Cre mice that express Cre under the parvalbumin (PV) promoter, and performed an RO injection of Soma-jGCaMP8 combined with local injections of an AAV5 vector expressing a floxed hM4D DREADD receptor. Indeed, this led to co-expression of both constructs in putative PV neurons and uniform expression of jGCaMP8 in surrounding neurons (**Fig. 6a**). This was verified by post-mortem histology (**Fig 6b**).

Another opportunity by combining uniform GECI expression with other transgenics is to identify specific populations of neurons by labeling with a fluorescent protein outside the color range of traditional GCaMPs. To this end, we again used PV-Cre mice and performed RO injections

of a Cre-dependent TdTomato PHP.eB virus. We observed highly selective labeling of PV neurons, in both *in vivo* and histological samples (**Fib. 6c**).

Finally, we tested the red-shifted GECI jRexGeco, a long stokes-shift version of the red GECI RGECO optimized for two-color imaging with a single laser source. Using the same 920nm laser as for green GECIs, jRexGECO was even brighter than jGCaMP8s. This indicates that jRexGECO could be a viable GECI to use in combination with imaging axonal activity using a green-shifted Ca²⁺ indicator (e.g.^{20,21}). Notably, while jRexGECO was very bright, its slow response kinetics and minute changes in calcium activity (approximately 10% deviation from baseline fluorescence) may be a limiting factor.

Figure 6: Applications of systemic GECI expression. **A:** experimental overview for GECIs expressed by RO injection and Cre-dependent hM4D expressed by local injection. **B:** RO injection of Cre-dependent TdTomato in PV-Cre mice lead to strong expression of tdTomato across cortex (left: example average intensity projection of 2000 frames). The selectivity to PV expressing neurons was verified by histology (right panel). **C:** RO injection of the red-shifted GECI jRexGECO. Scale bar indicate 250 μ m Example image

DISCUSSION

Engineered AAV serotypes with high affinity for the central nervous system that can be delivered intravenously represent a minimally invasive and low-cost method for introducing genetic payloads into the brain. Yet, these new serotypes, notably PHP.eB, have not been much used to deliver GECIs, despite obvious advantages in terms of animal welfare, cost, productivity and experimental flexibility. Previous work shows that widefield imaging with

systemically administered GCaMP6f is feasible using other promoters than synapsin^{22,14}. In our own preliminary experiments we experienced that typical GECIs (such as GCaMP6f) were not bright enough to be compatible with systemic administration. Here, we screened 14 GECIs and two fluorescent probes and show that newer iterations of jGCaMPs, particularly jGCaMP7s, jGCaMP8s and m, are indeed sufficiently bright for two-photon in-vivo calcium imaging when administered intravenously in PHP.eB AAVs. We also observed strong neuropil signals from these sensors which may influence accuracy of individual neuron activity, regardless of administration route. By fusing the latest jGCaMP variants with soma-targeting peptides we overcame this problem. Remarkably, we show that our Soma-jGCaMP8 and Ribo-jGCaMP8 outperform existing GECIs using both systemic and local virus injections.

An intravenous AAV injection in the retro-orbital sinus can be performed in a minute or two and requires very little training. The procedure is substantially less invasive than stereotaxic/intracranial injections. For the work presented here, one person with no formal training, successfully performed RO injections in 16 animals in 45 minutes. The intravenous injection provides largely uniform expression across the mouse brain, which is stable over extended time periods. This stands in contrast to local virus injections that often result in excessive expression leading to cell death. We note that in our hands, stable expression was resulting both from the administration route and the PHP.eB serotype. The expression of locally injected PHP.eB GECIs is also far more shielded from over-expression and toxicity compared to traditional AAV serotypes like AAV9, albeit not to the same level as RO injected PHP.eB virus.

Despite the many advantages of intravenously injected virus for GECI delivery, it has one considerable drawback; intravenous administration requires a large dose of virus per animal. If all viruses are purchased from commercial vendors, this could be prohibitively expensive. On the other hand, if viruses are produced in-house or by a local virus core, scaling up production to suitable levels is relatively inexpensive, and was not an issue for our experiments. Performing injections in younger animals will substantially reduce the amount of virus required. Another strategy which has been employed, is to use a stronger promoter such as CAG²³. Unlike the Synapsin promoter which is commonly used in neuroscience, CAG would not limit expression to neurons, and despite the strong tropism of PHP.eB AAV to neurons, this would result in some glial cells expressing GCaMP. This could be prevented if a flexed construct is used, but this would introduce the need for transgenic lines or an additional Cre expressing virus. An additional caveat concerning the PHP.eB and AAV9, is that we find a clear bias for layer 5, striatum, CA2 and subiculum regions. While the bias towards cortical layer 5 might be explained by the large cell volumes and thus higher capacity for transgene

production, this does not appear to be a common feature for the preferred brain areas. An alternative explanation might be that differences in vascularization is determinant for expression levels. However, this is at least unlikely for e.g. CA2 of hippocampus^(24,25) which exhibit strikingly strong expression compared to neighboring hippocampal areas. If the reason for expression differences are identified and reduced in future iterations of synthetic AAV serotypes, less virus may be required to achieve sufficient brightness in the upper layers of cortex for *in vivo* imaging.

The need for high brightness of the GECI for systemic administration also caused neuropil contamination of the signals. We therefore made use of two soma-targeting strategies that restricted expression to the cell soma. Moreover, we show that EE-RR soma-targeting led to highly stable expression which was already visible after two weeks, while ribosome-tethering reduced the brightness to such an extent that we did not observe cells during in-vivo imaging until 4-6 weeks after injection. Nonetheless, imaging could be performed using reasonable laser power 6 weeks after injection, and the ribosome-tethering led to highly selective expression in the cell soma. For local injections, ribosome-tethering showed very high density of cell labeling, but again the expression was slow. In general, soma-targeting GECI expression leads to improved signal-to-noise and the possibility to detect activity from a higher number of cells as their activity is not masked by neuropil activity. We also observed that automatic cell detection in suite2p was more accurate and required smaller data sets.

A major challenge when using transgenic animal models to express GECIs is the need for driver lines with general promoters preventing the use of other transgenics. Moreover, co-expression of several viruses, at least in our hands, often proves difficult. In contrast, we show that RO injected PHP.eB virus is compatible with transgenic lines and co-expression of another virus to obtain cell specific expression of e.g. a chemogenetic receptor to manipulate their activity or labelling a specific cell population.

In summary, we present a suite of viral vectors for use with both systemic and local administration which show remarkably high performance and sustainable expression over long periods of time. Due to the simplicity of the methods, high experimental flexibility, low cost and high performance, we believe that these soma-targeted GECI constructs are promising candidates to replace transgenic animal models for GECI expression.

MATERIALS & METHODS

GECI Plasmids (*references in hyperlink for each plasmid*)

All plasmids were transformed into NEB Stable (NEB) competent cells for amplification, and purified using the Zymopure II maxiprep kit (Zymo Research). To obtain “Soma” tagged GCaMP8, pAAV-Syn-SomaGCaMP7 was digested with HpaI and EcoRI to isolate the linker and Soma-tag. The fragment was then ligated into AAV-hSyn-GCaMP8s, m and f, which was previously digested using the same restriction enzymes. pAAV-Syn-SomaGCaMP7¹⁶ was a gift from Edward Boyden (http://n2t.net/addgene:158759;RRID:Addgene_158759). AAV-syn-jGCaMP8s-WPRE¹⁸ was a gift from GENIE Project (http://n2t.net/addgene:162374;RRID:Addgene_162374), as well as jGCaMP8f (Addgene:162376) and jGCaMP8m (Addgene:162376). To obtain “Ribo” tagged GCaMP8, pyc126m (Ribo-GCaMP6m) was digested with HpaI and EcoRI to isolate the linker and Ribo-tag. The fragment was then ligated into AAV-syn-GCaMP8s, m and f, previously linearized using the same restriction enzymes. pycm126¹⁷ was a gift from Jennifer Garrison & Zachary Knight (http://n2t.net/addgene:158777;RRID:Addgene_158777). To obtain Synapsin promoter expressed jRexGeco, the jRexGeco coding sequence was cut from CMV-jRexGeco using BamHI and EcoRI, and inserted into a pAAV-Syn-Chr2 plasmid, which was digested with the same restriction enzymes, removing the coding sequence of Chr2 and replacing it with jRexGeco. jRexGeco expressed under a CMV promoter was a gift from Neurophotronics^{26,27}. The hSyn plasmid, pAAV-Syn_ChR2(H134R)-GFP²⁸ was a gift from Edward Boyden (http://n2t.net/addgene:58880;RRID:Addgene_58880). Additional plasmids, GCaMP6f, somaGCaMP6f, jGCaMP7f, jGCaMP7s, mNeonGreen and flex-tdTomato were acquired from addgene and were not modified in this paper. pAAV.Syn.GCaMP6f.WPRE.SV40²⁹ was a gift from Douglas Kim & GENIE Project (http://n2t.net/addgene:100837;RRID:Addgene_100837). pGP-AAV-Syn-jGCaMP7f-WPRE² was a gift from Douglas Kim & GENIE Project (http://n2t.net/addgene:104488;RRID:Addgene_104488). pGP-AAV-Syn-jGCaMP7s-WPRE² was a gift from Douglas Kim & GENIE Project (http://n2t.net/addgene:104487;RRID:Addgene_104487). pAAV-CAG-mNeonGreen¹³ was a gift from Viviana Gradinaru (http://n2t.net/addgene:99134;RRID:Addgene_99134). pAAV-FLEX-tdTomato was a gift from Edward Boyden (http://n2t.net/addgene:28306;RRID:Addgene_28306). Plasmids for AAV packaging were acquired from Addgene and Penn Vector core, which is now available from Addgene. Only PHP.eB serotype viruses were used in this paper, except for the cre-dependent DREADD-mCherry, pAAV-hSyn-DIO-hM4D(Gi)-mCherry³⁰ which was a gift from Bryan Roth (Addgene viral prep # 44362-AAV5;http://n2t.net/addgene:44362;RRID:Addgene_44362). The PHP.eB serotype plasmid, pUCmini-iCAP-PHP.eB¹³ was a gift from Viviana Gradinaru

(http://n2t.net/addgene:103005;RRID:Addgene_103005). The DeltaF6 helper plasmid, pAdDeltaF6, was a gift from James M. Wilson (http://n2t.net/addgene:112867;RRID:Addgene_112867).

AAV production: Viral vectors were produced in house according to the protocol developed by Rosemary C Challis et al³¹. Briefly, AAV HEK293T cells (Agilent) were cultured in DMEM with 4.5 g/L glucose & L-Glutamine (Lonza), 10% FBS (Sigma) and 1% PenStrep (Sigma), in a 37°C humidified incubator. The cells were thawed fresh and split at ~80% confluency until four 182.5cm² flasks were obtained for each viral prep. The cells were transfected at 80% confluency and the media was exchanged for fresh media directly before transfection. The cells were triple transfected with dF6 helper plasmid and PHP.eB serotype plasmid. Polyethylenimine (PEI), linear, molecular weight (MW) 25,000 (Polysciences, cat. no. 23966-1) was used as the transfection reagent. Media was harvested three days after transfection and kept at 4°C, and media with cells was harvested five days after transfection, and combined with the first media harvest. After 30 min centrifugation at 4000 g, the cell pellet was incubated with SAN enzyme (Arctic enzymes) for 1 hour. The supernatant was mixed 1:5 with PEG and incubated for 2 hours on ice, then centrifuged at 4000g for 30 minutes to obtain a PEG pellet containing the virus. The PEG pellet was dissolved in SAN buffer and combined with the SAN cell pellet for incubation at 37°C for 30 minutes. To purify the AAV particles, the suspension was centrifuged at 3000 g for 15 minutes. The supernatant was loaded on the top layer of an Optiseal tube with gradients consisting of 15%, 25%, 40% and 60% iodixanol (Optiprep). Ultracentrifugation was performed for 2.5 hours in 18°C at 350'000g in a type 70 Ti rotor. The interface between the 60% and 40% gradient was extracted along with the 40% layer, avoiding the protein layer on top of the 40% layer. The viral solution was filtered through a Millex- 33mm PES filter before adding to an Amicon Ultra-15 centrifugal filter device (100-kDa molecular weight cutoff, Millipore). A total of four washes with 13 ml DPBS were performed at 3000 g before concentration to a volume of ~750ul. Viral solutions were sterilized through 13 mm PES syringe filters 0.2 µm (Nalgene), and stored in sterile screw-cap vials at 4°C.

Viral titres were determined using qPCR with primers targeting AAV2 ITR sites³² (Table S1), following the “[AAV Titration by qPCR Using SYBR Green Technology](#)” protocol by Addgene¹⁰. Briefly, 5 ul of viral sample was added to 39 ul ultrapure H₂O, 5 ul 10x DNase buffer, 1 ul DNase, and incubated at 37°C for 30 minutes to eliminate all DNA not packaged into AAV capsids. 5 ul of the DNase treated sample was added to a reaction mix consisting of 10 ul 2x SYBR master mix, 0.15 ul of each primer (100uM) and 4.7 ul nuclease free H₂O. Cycling conditions for the qPCR program were: 98°C 3 min / 98°C 15 sec / 58°C 30 sec / read plate/ repeat 39x from step 3 / melt curve.

In addition to the constructs tested in the manuscript, we also made Soma-jGCaMP8f and Ribo-jGCaMP8f. All plasmids will be deposited to Addgene.

Experimental animals: All work with experimental animals was performed at the animal facility at the Department of Biosciences, Oslo, Norway, in agreement with guidelines for work with laboratory animals described by the European union (directive 2010/63/EU) and the Norwegian Animal Welfare Act from 2010. The experiments were approved by the National Animal Research Authority of Norway (Mattilsynet, FOTS ID 14680).

Four weeks old male C57/BL6j mice were purchased from Janvier Labs, and housed in GM500 IVC cages in groups of four. After an acclimation period of two weeks, the animals were split into two mice per cage prior to virus injections. One week after injections, the mice were housed individually, and remained single-housed for the duration of the experimental period. The housing room had a 12/12 hour light cycle, with lights off at noon. In the light phase, light intensity in the room was 215 lux, and in the cages varied from 20-60 lux, depending on position in the rack. All experiments were performed in the dark phase. For enrichment purposes, each cage had a running wheel and large amounts of nesting material, and the mice had *ad libitum* access to food and water.

Retro-orbital injections: pairs of mice were randomly assigned to a viral vector. The mice were placed in an induction chamber and briefly anesthetized by isoflurane, before they were transferred to a mask with 1-2% isoflurane delivered. An eye drop of local anesthetic (oxybuprocaine 4mg/mL, Bausch Health), was applied to the right eye, and one minute later 100-150 μ L of virus injected into the retro-orbital sinus using a U100 insulin syringe (BD micro-fine 0.3mL, 30 gauge needle). The volume was determined based on the animal's weight (**ref**). The surface of the eye was flushed with saline and cleaned with a cotton tip. The mice were then placed back in the home cage and monitored for 10-15 minutes, before they were returned to the housing room. All animals fully recovered within minutes. In one single mouse, we observed eye damage to the injected side after one week. It is not clear whether this resulted from the injection or resulting from the high incidence of eye abnormalities in the c57bl6 mouse strain³³.

Surgical procedures: The mice were anesthetized by an intraperitoneal injection of a ketamine/xylazine cocktail (Ketamin 12.5 mg/kg, Pfizer; xylazine 5mg/kg, Bayer Animal Health GmbH). The top of the head was shaved and the animals placed on a heating pad in a stereotaxic frame with a mouse adapter (Model 926, David Kopf Instruments). The eyes were covered with white vaseline to prevent drying and to protect them from light. Dexamethasone

(5 mg/kg, MSD Animal Health) was delivered via an intramuscular injection to prevent edema, and local anesthetic bupivacaine (Aspen) injected in the scalp. In a subset of animals, the mice were anesthetized by isoflurane (3.5% induction, 1-1.5% maintenance) and additionally injected subcutaneously with buprenorphine (0.05mg/kg, Indivior Ltd) for analgesia. The skin was cleaned with 70% ethanol and chlorhexidine, and a small piece of skin covering the top of the skull was cut away. The periosteum and other membranes were removed using fine forceps and cotton swabs, and the surface of the skull slightly scored with a scalpel. A custom titanium head post was attached using a few drops of cyanoacrylate, and secured using VetBond (3M) and C&B Metabond (Parkell). A 3.0 mm craniotomy was made using a Perfecta 300 hand-held drill (W&H) with a 0.5 mm drill bit (Hager & Meisinger GmbH), centered over primary visual cortex (center coordinates were 2.5 mm ML and 1 mm AP relative to lambda). Custom cranial windows were made by attaching a 3.0 mm diameter round glass (Tower Optical) with 0.45 mm thickness to a 5.0 mm diameter glass (Warner Instruments, USA) with 100 μ m thickness using Norland Optical adhesive (Thorlabs GmbH, Germany) under UV light. The cranial window was implanted and secured with C&B Metabond, and a 3D printed light shield was attached to the head post with black dental acrylic⁷. At the end of the procedures, the mice were injected subcutaneously with 0.3 mL 0.9% saline, meloxicam (5 mg/kg, Boehringer Ingelheim VetMedica GmbH) and Antisedan (0.0012 mg/kg, Orion Pharma). Injections of metacam were repeated for three days.

In a subset of mice, bone growth partially obscured the view through the cranial window over the course of the experimental period. In these cases, the animal was anesthetized by isoflurane, the window removed to clear away any bone growth and other debris, and a new cranial window implanted⁷. The procedure was performed one week prior to imaging to allow the tissue to recover from potential damage during bone removal.

Local virus injections: glass capillaries (OD 1.14 mm; ID 0.53 mm) were pulled and beveled at a 40 degree angle³⁴, and mounted in a NanoJect 3 (Drummond Scientific, USA). The pipette was front loaded with the virus solution and 150 nL injected at a depth of 350-500 μ m below the dura, in 5 nL steps. After the last injection, the pipette was left in the tissue for five minutes before retraction and loading of a new pipette. Two to three different constructs were injected per animal, spaced at least 700 μ m apart. After the final injection, the exposed brain surface was cleaned with saline and a cranial window implanted as described above.

Widefield imaging: Widefield imaging was used to monitor the expression levels of the Ca²⁺ sensors and quality of the cranial windows. The mice were head-fixed on a custom 3D-printed running wheel using optical posts that were mounted to the optical table, holding clamps (Standa) and modified ball-joints (Thorlabs GmbH) allowing for adjustments in AP elevation.

Images were acquired by a Canon EOS 4000D camera through a 5X Mitutoyo long working-distance objective (0.14 NA) in an Olympus BX-2 microscope. The light source was a xenon arc Lambda XL lamp (Sutter Instruments) with 480/545nm and 560/635 nm filters (#39002 and #39010, Chroma). All animals were imaged using two sets of parameters at each time point, with exposure times of 600 and 2000 ms, and ISO of 100 and 400, respectively. The mice ran freely in darkness during imaging. In addition, widefield videos were captured at 25Hz during both spontaneous activity (in darkness) and with visual stimulation.

Two-photon imaging: For *in vivo* two-photon imaging we used a resonant-galvo Movable Objective Microscope (MOM, Sutter Instruments) with a MaiTai DeepSee laser (SpectraPhysics) set to a wavelength of 920 nm (990 nm used for TdTomato). The main objective used for screening was a 10X objective (TL-10x2P, 0.5 NA, 7.77 mm working distance, Thorlabs), giving a field of view of approximately 1665 x 1390 μm . In mice with successful GCaMP imaging we also imaged at lower depths (200-500 μm) using a Nikon 16X objective (NA 0.8), giving a field of view of approximately 1050 x 890 μm . The laser was controlled by a pockel's cell (302 RM, Conoptics), and fluorescence detected through Chroma bandpass filters (HQ535-50-2p and HQ610-75-2p, Chroma) by PMTs (H10770PA-40, Hamamatsu). Images were acquired at 30.9 Hz using MCS software (Sutter Instruments). Output power at the front aperture of the objective was measured prior to each imaging session with a FieldMate power meter (Coherent) and set to 50 mW, unless mentioned otherwise. The microscope was tilted to an angle of 6-12 degrees during imaging to match the surface of the brain.

Co-expression of GCaMP and cell-specific DREADDs: PV-Cre mice (Jackson Laboratories, strain #017320) were injected with Soma-jGCaMP8s as described above. Two weeks later, 150nL of pAAV5-hSyn-DIO-hM4D(Gi)-mCherry (#44362, Addgene) was injected into the cortex, and a cranial window implanted.

Visual stimulus: Sinusoidal drifting ratings were generated using the open-source Python software PsychoPy³⁵, and synchronized with two-photon imaging through a parallel port and PCIe-6321 data acquisition board (National Instruments). We used drifting gratings of 3 orientations (0, 135 and 270 degrees) with a spatial frequency of 4 cycles per degree and temporal frequency of 2Hz. Stimulus was shown for 3 seconds, interleaved with an 8 second grey screen period.

Two-photon imaging analysis: Motion-correction and automatic detection of regions of interest (ROIs) was performed using suite2p³⁶. The data was then manually curated, and

selected ROIs analyzed using custom Python scripts. $\Delta F/F_0$ was defined as $(F - 0.7 * F_{neu}) / F_0$, where F is the raw fluorescence, F_{neu} is the neuropil fluorescence as defined by suite2p and F_0 is the mean of the tenth percentile of F . The notebook used to generate the calcium trace figures is available on Github (github.com/sverreg/calciumtraceln).

Widefield imaging analysis: To measure changes in fluorescence over time in widefield imaging videos, we used ImageJ (Fiji). Videos were spatially downsampled, and regions of interest (ROIs) selected in the center of the cranial window. Changes in relative fluorescence was calculated by $(F - F_0) / F_0$, where the baseline fluorescence (F_0) was defined as the mean fluorescence across all frames from “spontaneous” and “visual stimulus” runs in the entire cranial window. Calcium signal traces were obtained from the average fluorescence intensity in an approximately 200 μ m diameter circular area.

Histology: Six weeks after virus injection, all animals were deeply anesthetized by an intraperitoneal injection of Euthasol (pentobarbital sodium 100 mg/kg, Le Vet) and intracardially perfused with PBS followed by 4% paraformaldehyde (PFA) in PBS. Brains were dissected out and postfixed for 24 hours followed by cryoprotection in 30% sucrose in PBS for 48 hours. 40 μ m coronal sections were cut with a cryostat. All sections were stained free-floating on constant agitation. The sections were rinsed three times in PBS followed by blocking in 2% bovine serum in 0.3 % Triton X-100 in PBS for 1 hour before incubation with primary antibody in blocking solution overnight (all antibodies used are listed in **Table 3**). After rinsing, sections were incubated with secondary antibodies in PBS for 1 hour. Sections were then mounted on Superfrost Plus adhesion slides and dried for 2 hours. After rinsing in dH₂O and additional drying for 1 hour, sections were coverslipped with mounting medium (Ibidi). Tile scans were acquired with 20% overlap on an Andor Dragonfly spinning-disc microscope with a motorized platform, and stitched using Fusion software (Bitplane). The Andor Dragonfly was built on a Nikon TiE inverted microscope equipped with a Nikon PlanApo 10x/0.45 NA objective.

Antibody	Supplier	RRID
Chicken anti-GFP	Invitrogen	AB_2534023
Rabbit anti-NeuN	Abcam	AB_2532109
Goat anti-TdTomato	Sicgen	AB_2722750
Rabbit anti-parvalbumin	Swant	AB_2631173
Donkey anti-goat IgG, CF 568 conj.	Biotium	AB_10854239

Goat anti-chicken IgG, AF 488 conj,	Invitrogen	AB_142924
Goat anti-rabbit IgG, AF 647 conj,	Invitrogen	AB_2535813
Chicken anti-rabbit IgG, AF 488 conj.	Invitrogen	AB_2535859

Table 3: List of antibodies used for post-mortem histology.

AUTHOR CONTRIBUTIONS

	Concept. and experimental design	Plasmid design and assembly	Virus production	Surgeries and <i>in vivo</i> imaging	Histology, microscopy	Data analysis	Writing the manuscript
SG	XX	XX	XX		X	XX	XX
IN	XX			XX	XX	XX	XX
GHV	X	XX	XX				X
VB		X	XX				
KKL	XX			XX	XX	XX	XX
MF	XX					X	X

All authors have read the final version of the manuscript. The authors report no conflicts of interest.

Acknowledgements

We thank Dr. Ane Charlotte Chistensen and Dr. Jennifer L. Hazen for assistance with establishment of the RO injection technique, and the Instrumentation Lab at the Dept of Bioscience. Imaging of histological sections was performed at the NorMIC microscopy platform at the Dept. of Bioscience, University of Oslo.

REFERENCES

1. Inoue, M. *et al.* Rational Engineering of XCaMPs, a Multicolor GECI Suite for In Vivo Imaging of Complex Brain Circuit Dynamics. *Cell* **177**, (2019).
2. Dana, H. *et al.* High-performance calcium sensors for imaging activity in neuronal populations and microcompartments. *Nat. Methods* **16**, (2019).
3. Madisen, L. *et al.* Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. *Neuron* **85**, (2015).
4. Daigle, T. L. *et al.* A Suite of Transgenic Driver and Reporter Mouse Lines with Enhanced Brain-Cell-Type Targeting and Functionality. *Cell* **174**, (2018).
5. Wekselblatt, J. B., Flister, E. D., Piscopo, D. M. & Niell, C. M. Large-scale imaging of cortical dynamics during sensory perception and behavior. *J. Neurophysiol.* **115**, (2016).
6. Steinmetz, N. A. *et al.* Aberrant cortical activity in multiple GCaMP6-expressing transgenic mouse lines. *eNeuro* **4**, (2017).
7. Goldey, G. J. *et al.* Removable cranial windows for long-term imaging in awake mice. *Nat. Protoc.* **9**, (2014).
8. Kim, J. Y., Grunke, S. D., Levites, Y., Golde, T. E. & Jankowsky, J. L. Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. *J. Vis. Exp.* (2014) doi:10.3791/51863.
9. Foust, K. D. *et al.* Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. *Nat. Biotechnol.* **27**, (2009).
10. Lampe, S. E. G., Kaspar, B. K. & Foust, K. D. Intravenous injections in neonatal mice. *J. Vis. Exp.* (2014) doi:10.3791/52037.
11. Hamodi, A. S., Sabino, A. M., Fitzgerald, N. D., Moschou, D. & Crair, M. C. Transverse sinus injections drive robust whole-brain expression of transgenes. *Elife* **9**, (2020).
12. Yang, Y. *et al.* Improved calcium sensor GCaMP-X overcomes the calcium channel perturbations induced by the calmodulin in GCaMP. *Nat. Commun.* **9**, (2018).
13. Chan, K. Y. *et al.* Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. *Nat. Neurosci.* **20**, (2017).
14. Michelson, N. J., Vanni, M. P. & Murphy, T. H. Comparison between transgenic and AAV-PHP.eB-mediated expression of GCaMP6s using in vivo wide-field functional imaging of brain activity. *Neurophotonics* **6**, (2019).
15. Yardeni, T., Eckhaus, M., Morris, H. D., Huizing, M. & Hoogstraten-Miller, S. Retro-orbital injections in mice. *Lab Animal* vol. 40 (2011).
16. Shemesh, O. A. *et al.* Precision Calcium Imaging of Dense Neural Populations via a Cell-Body-Targeted Calcium Indicator. *J. Clean. Prod.* (2020) doi:10.1016/j.neuron.2020.05.029.
17. Chen, Y. *et al.* Soma-Targeted Imaging of Neural Circuits by Ribosome Tethering. *Neuron* **107**, (2020).
18. Y. Zhang, M. Rózsa, D. Bushey, J. Zheng, D. Reep, G. J. Broussard, A. Tsang, G. Tsegaye, R. Patel, S. Narayan, J. X. Lim, R. Zhang, M. B. Ahrens, G. C. Turner, S. S.-H. Wang, K. Svoboda, W. Korff, E. R. Schreier, J. P. Hasseman, I. Kolb, L. L. L. jGCaMP8 Fast Genetically Encoded Calcium Indicators. (2020) doi:10.25378/janelia.13148243.
19. Mathiesen, S. N., Lock, J. L., Schoderboeck, L., Abraham, W. C. & Hughes, S. M. CNS Transduction Benefits of AAV-PHP.eB over AAV9 Are Dependent on Administration Route and Mouse Strain. *Mol. Ther. - Methods Clin. Dev.* **19**, (2020).

20. Nelson, A. & Mooney, R. The Basal Forebrain and Motor Cortex Provide Convergent yet Distinct Movement-Related Inputs to the Auditory Cortex. *Neuron* **90**, (2016).
21. Broussard, G. J. *et al.* In vivo measurement of afferent activity with axon-specific calcium imaging. *Nat. Neurosci.* **21**, (2018).
22. Allen, W. E. *et al.* Global Representations of Goal-Directed Behavior in Distinct Cell Types of Mouse Neocortex. *Neuron* **94**, (2017).
23. Jackson, K. L., Dayton, R. D., Deverman, B. E. & Klein, R. L. Better targeting, better efficiency for wide-scale neuronal transduction with the synapsin promoter and AAV-PHP.B. *Front. Mol. Neurosci.* **9**, (2016).
24. Ji, X. *et al.* Brain microvasculature has a common topology with local differences in geometry that match metabolic load. *Neuron* **109**, (2021).
25. Kirst, C. *et al.* Mapping the Fine-Scale Organization and Plasticity of the Brain Vasculature. *Cell* **180**, (2020).
26. Molina, R. S. *et al.* Understanding the Fluorescence Change in Red Genetically Encoded Calcium Ion Indicators. *Biophys. J.* **116**, (2019).
27. Wu, J. *et al.* A long Stokes shift red fluorescent Ca²⁺ indicator protein for two-photon and ratiometric imaging. *Nat. Commun.* **5**, (2014).
28. Boyden, E. S., Zhang, F., Bamberg, E., Nagel, G. & Deisseroth, K. Millisecond-timescale, genetically targeted optical control of neural activity. *Nat. Neurosci.* **8**, (2005).
29. Chen, T. W. *et al.* Ultrasensitive fluorescent proteins for imaging neuronal activity. *Nature* **499**, (2013).
30. Krashes, M. J. *et al.* Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. *J. Clin. Invest.* **121**, (2011).
31. Challis, R. C. *et al.* Systemic AAV vectors for widespread and targeted gene delivery in rodents. *Nat. Protoc.* **14**, (2019).
32. Aurnhammer, C. *et al.* Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. *Hum. Gene Ther. Methods* **23**, (2012).
33. Smith, R. S., Roderick, T. H. & Sundberg, J. P. Microphthalmia and associated abnormalities in inbred black mice. *Laboratory Animal Science* vol. 44 (1994).
34. Canfield, J. G. Dry beveling micropipettes using a computer hard drive. *J. Neurosci. Methods* **158**, (2006).
35. Peirce, J. *et al.* PsychoPy2: Experiments in behavior made easy. *Behav. Res. Methods* **51**, (2019).
36. Pachitariu, M. *et al.* Suite2p: beyond 10,000 neurons with standard two-photon microscopy. *bioRxiv* (2016) doi:10.1101/061507.

A **B**

RO injection jGCaMP7f

RO injection Soma-jGCaMP8m

jGCaMP7f Soma-jGCaMP8m

C

RO GECl injection

Local GECl injection

DZ = 100 μm Z = 200 μm Z = 300 μm Z = 400 μm

A

B

A

B

A

B

C

A

B RO DIO-tdT injection in PV-Cre mouse

C RO jRexGECO injection